Α5IA
# Α5IA

$α_5IA$ (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the $GABA_A$ receptor. It binds to the $α_1,$ $α_2,$ $α_3$ and $α_5$ subtypes.

## In Vivo Electrophysiology

Recordings of local field potentials indicate that oral administration of α5IA increases the amplitude of sharp wave ripples which are implicated in memory function in adult wild type rats. It is intriguing to note that the increase in ripple amplitude is not seen in adult male TgF344-AD rats which express human β-amyloid precursor protein (with the Swedish mutation) and human presenilin-1 (with a Δ exon 9 mutation).

